This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $2,467,574 to Boston Medical Center Corporation (BMC) to develop and evaluate the efficacy of a universal overdose prevention intervention to be delivered in primary care settings. The intervention aims to increase youth awareness of the risks of fentanyl and other emerging drugs, knowledge of strategies to reduce overdose risk, and recognition and response to overdose. In the initial R61 phase, BMC will pilot the intervention in their pediatric and family medicine primary care clinics to assess acceptability and feasibility. If the intervention is found to be acceptable and feasible, BMC will transition to evaluating its efficacy in a larger randomized controlled trial during the subsequent R33 phase. The goal is to benefit youth and public health by preparing young people to reduce their overdose risk and recognize and respond to overdoses.
Generated 3/4/25, 2:18 AM